This study clarified CEA ≥ 53.74 ng/ml, SCC − Ag ≥ 1.49 ng/ml, IL − 10 ≥ 16.95 pg/ml, and IL − 6 ≥ 0.76 pg/ml were risk factors impacting the efficacy of LC immunotherapy, indicating that elevated tumor markers and inflammation could affect the efficacy of immunotherapy in patients. This evidence concerns the gene SERPINB3 and neoplasm.